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Abstract
Purpose Remote ischemic preconditioning protects peripheral organs against prolonged ischemia/reperfusion injury via circu-
lating protective factors. Preconditioning with helium protected healthy volunteers against postischemic endothelial dysfunction.
We investigated whether plasma from helium-treated volunteers can protect human umbilical vein endothelial cells (HUVECs)
against hypoxia in vitro through release of circulating of factors.
Methods Healthy male volunteers inhaled heliox (79% helium, 21% oxygen) or air for 30 min. Plasma was collected at baseline,
directly after inhalation, 6 h and 24 h after start of the experiment. HUVECs were incubated with either 5% or 10% of the plasma
for 1 or 2 h and subjected to enzymatically induced hypoxia. Cell damage was measured by LDH content. Furthermore, caveolin
1 (Cav-1), hypoxia-inducible factor (HIF1α), extracellular signal-regulated kinase (ERK)1/2, signal transducer and activator of
transcription (STAT3) and endothelial nitric oxide synthase (eNOS) were determined.
Results Prehypoxic exposure to 10% plasma obtained 6 h after helium inhalation decreased hypoxia-induced cell damage in
HUVEC. Cav-1 knockdown in HUVEC abolished this effect.
Conclusions Plasma of healthy volunteers breathing helium protects HUVEC against hypoxic cell damage, possibly involving
circulating Cav-1.
Keywords Endothelial conditioning . Remote . Helium . Ischemic preconditioning . Caveolin-1
Introduction
Noble gases like helium [1, 2] and xenon [3–5] can induce
preconditioning and protect organs against ischemia-
reperfusion (I-R) injury. The mechanism behind helium pre-
conditioning remains unclear, but involvement of the
reperfusion injury salvage kinase (RISK) pathway and its
downstream targets [6, 7], the mitochondrial adenosine
triphosphate–regulated potassium channel (KATP) [8] and cal-
cium sensitive potassium channel have been described [9, 10].
These mediators are all located on the mitochondria, suggest-
ing that the mechanism of helium conditioning might congre-
gate on this level.
Caveolins are structural proteins that are essential in the
formation of cholesterol- and sphingolipid-enriched invagina-
tions of the plasma membrane called Bcaveolae^ [11, 12].
Caveolae, a subtype of lipid rafts, contain a scaffolding do-
main that anchors and regulates proteins and influences cellu-
lar processes, including vascular transport and signal trans-
duction [12]. These signalling molecules that aggregate into
multiprotein complexes known as signalosomes are continu-
ously forming and dissociating under basal and stimulated
conditions and are regulated by caveolins [13].
Many of the protein complexes involved in organ pro-
tection via preconditioning are known to bind to the
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scaffolding domain of caveolins and are regulated by
caveolins [14, 15]. As such, caveolins are critically in-
volved in ischemic preconditioning [16].
Ischemic preconditioning not only protects against
ischemia-reperfusion injury on a local level in multiple or-
gans, but also protects remote tissues, a phenomenon known
as remote ischemic preconditioning (RIPC) via release of cir-
culatory protective factors [17]. It was shown that plasma
obtained from healthy volunteers undergoing RIPC protects
against hypoxia-induced damage in endothelial cells, suggest-
ing involvement of a potential humoral mediator for protec-
tion [18]. Whether noble gases mediate a release of humoral
factors to initiate an RIPC-like effect is yet unknown.
A previous in vitro study showed that helium treatment of
endothelial cells indeed lowers levels of caveolin-1 and in-
creases levels of circulating caveolin-1 in the supernatant of
these cells [19]. Such data support the hypothesis that circu-
lating factors in the blood streammay be involved in inducing
organ protection by helium.
All blood vessels are lined by a layer of endothelial cells,
and the endothelium is the first contact site for a humoral
mediator of RIPC. The endothelium may interact with the
mediator and either directly or indirectly transfer the RIPC
stimulus to the target organ. We hypothesised that plasma
collected from human volunteers exposed to helium inhalation
contains a helium-induced release of cellular factors contain-
ing cell protective features and that caveolins may be central
to this effect. As the endothelium is the first contact site for a
remote stimulus, we investigated whether plasma from human
volunteers would protect against hypoxia in endothelial cells.
Methods
The study was approved by the ethical committee of the
Academic Medical Centre, Amsterdam (http://www.
trialregister.nl/NTR4507) and was conducted in accordance
with the International Conference on Harmonisation on Good
Clinical Practice Guidelines and the Declaration of Helsinki.
After obtaining informed consent, a total of 20 healthy,
non-smoking, male volunteers (age 20–55) were included in
this explorative crossover study. Exclusion criteria for the vol-
unteers were any form of chronic disease, smoking and history
of allergic reaction to medication. Baseline levels of
haemoglobin, leucocytes and C-reactive protein were deter-
mined before each experimental cycle, and no difference was
observed between groups (see Table 1). All volunteers were
treated in the Academic Medical Centre Amsterdam from 16
June 2014 until 21 August 2014. One volunteer did not com-
plete the study and was removed from analysis.
Thus, all observations reflect the results of n = 19 besides the
knockdown experiments. However, for the knockdown exper-
iments (Fig. 4), we focused on the primary outcome of the
study, namely the protection of plasma against the hypoxia-
induced cell damage, and at the time point where the initial
protection was seen (Fig. 2). The knockdown experiments were
very resource consuming and took most of the plasma we had
left, so based on this, we were not able to measure LDH in the
knockdown cells at the time points 30 min and 24 h.
Experiments were performed in a quiet, temperature-
controlled room. Twelve hours prior to the start of the exper-
iments, volunteers refrained from alcohol or caffeine-
containing drinks and were denied heavy physical exercise.
All volunteers underwent two experimental cycles (separated
by 2 weeks), breathing either 30 min of heliox (79% He/21%
O2, BOC, Mordon, UK) or air using a non-invasive delivery
system via a normal face mask with pressure support of 3-cm
H2O. None of the volunteers had any sign of dyspnoea or any
kind of stress; they were all normally breathing and calm.
Blood was collected before (baseline, T0) and directly after
inhalation of heliox or air (T1), as well as 6 h (T2) and 24 h
(T3) after start of the experiment by separate venous punctures
(see Fig. 1). Samples were collected in citrate vials (BD
Bioscience, Breda, the Netherlands) and stored at − 80 °C
after centrifugation (290×g for 10 min at 4 °C).
Cell Culture
HUVECs were collected from human umbilical veins as de-
scribed previously [19] (Waiver W12-167#12.17.096, Ethical
Committee AMC, Amsterdam). Experiments were performed
with cells of passages 3 and 4. HUVECs were identified using
antibodies against von Willebrand factor (data not shown).
Enzymatically Induced Hypoxia
Hypoxia was induced by enzymatic oxygen depletion using
4 U/ml glucose oxidase and 120 U/ml catalase as previously
described [18]. For this study, the concentration of hypoxia-
inducing enzymes was optimised after measuring oxygen
levels in cell culture medium using the OxyMini fibre optic
oxygen meter (World Precision Instruments, USA, Sarasota)
and OxyMicro Software v.00 04/2003. After hypoxia induc-
tion, cell culture plates were put in an airtight chamber
(Billups-Rothenberg, Del Mar, CA, USA), flushed with
Table 1 Biochemical data of volunteers
Control gas Helium
CRP (mmol/l) 1.1 ± 1.3 1.3 ± 1.9
Haemoglobin (mmol/l) 9.2 ± 0.5 9.2 ± 0.5
Leucocytes (mmol/l) 5.2 ± 0.9 5.5 ± 1.0
Data are represented as means ± SD. No significant differences were
observed between cycles
CRP C-reactive protein, Hb haemoglobin, L leucocytes
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nitrogen until the oxygen concentration was < 1% and kept in
the incubator at 37 °C for 24 h.
Experimental Protocol
Upon cell confluence, HUVECs were seeded onto gelatine-
coated 12-well plates 2 days prior to start of the subsequent
in vitro experiments. Before the start of enzymatically induced
hypoxia, cells were incubated at 37 °C for 1 or 2 h with
normoxic M199 (PAN Biotech, Aidenbach, Germany) con-
taining 5% or 10% of the plasma samples of the volunteers
(percentage as diluted in cell culture medium, each four time
points of the two experimental cycles; see Fig. 1).
Subsequently, this medium was replaced with hypoxic
M199, and respective plasma and plates were put in an airtight
chamber for 24 h. Cell culture medium of each well was col-
lected and frozen at − 20 °C after 24 h of hypoxia for colori-
metric lactate dehydrogenase (LDH) activity measurements
and enzyme-linked immune assay (ELISA). Cells were har-
vested and frozen at − 80 °C for western blot analysis.
Additional experiments were performed using small interfer-
ing RNA (siRNA) Cav-1-transfected HUVEC (n = 10).
Lactatdehydrogenase Measurement
and Enzyme-Linked Immune Assay
In the supernatant, LDH activity was measured by colorimet-
ric analysis using LDH kit (Biovision, Uithoorn, the
Netherlands) according to the manufacturer’s protocol. An
ELISA reader (Tecan, Crailsheim, Germany) was used to
measure light absorbance. Plasma levels of caveolin-1
(BlueGene, Shanghai, China) and eNOS (R&D Systems,
Minneapolis, USA) were determined by ELISA.
Western Blotting
Western blotting was performed as described previously
[19, 20]. In order to obtain all membrane-bound proteins
in the cell lysate, we performed ultrasonic lysis by
sonification with each sample. Overnight incubation with
primary antibodies was performed for caveolin-1 (Abcam,
Cambridge, UK 1:20,000); glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) (Abcam, Cambridge, UK, 1:5000);
HIF1α (Acr i s , Novus Bio log ica l , UK, 1:1000) ;
phosphoERK1/2 (Cell Signalling, Danvers, USA, 1:5000),
ERK1/2 (Cell Signalling, Danvers, USA, 1:5000),
phospho-eNOS and eNOS (Cell Signalling, Danvers,
USA, 1 :1000) , phosphoSTAT3 (R&D Sys t ems ,
Minneapolis, USA, 1:1000) or against STAT3 (R&D
Systems, Minneapolis, USA, 1:1000).
Membranes were washed for 3 × 5 min in tris-buffered sa-
line containing Tween buffer (TBST) before incubating with
the appropriate secondary antibody (IRdye, LI-COR, Bad
Homburg, Germany) for 1 h at room temperature. After a final
washing, membranes were scanned with the Odyssey infrared
imaging system (LI-COR, Bad Homburg, Germany), and
quantification of the signals was performed with Odyssey
Imaging Studio software (LI-COR, Bad Homburg, Germany).
Fig 1 Protocol outline. Healthy volunteers received either helium or
control gas via face mask in 2 cycles (separated by 2 weeks). Blood
samples were taken at baseline (T1) and 30 min (T2), 6 h (T3) and 24 h
(T4) after treatment (b). HUVECs were incubated with plasma and sub-
jected to 24 h of hypoxia, after which cells and supernatant were harvest-
ed for analysis
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Transfection with siRNA for Cav-1
We transfected HUVEC at a confluency of 50–80% with
siRNA for Cav-1 (caveolin-1 (sense) sequence (5′-3′)
CCCUAAACACCUCAACGAU(dT)(dT), Cav-1 (antisense)
sequence (5′-3′) AUCGUUGAGGUGUUUAGGG(dT)(dT),
Sigma-Aldrich, Zwijndrecht, The Netherlands) or negative
control siRNA (Silencer® Negative Control siRNA,
Ambion by Thermo Fischer Scientifics, Waltham, MA,
USA) using Lipofectamine RNAiMax (Invitrogen by
Thermo Fischer Scientifics, Waltham, MA, USA). siRNA
for Cav-1 or negative control siRNAwas used at a final con-
centration of 100 nM on the cells and was left on the cells for
24 h. After 72 h, cells were lysated to determine protein knock
down by western blot analysis or experiments were started.
Statistical Analysis
All data are shown as mean ± 95% CI. Statistical analyses
were performed using GraphPad Prism 7.0 (La Jolla, CA,
USA) software. Data were analysed for normal distribution
using the D’Agostino test. Student’s t test was used to analyse
parametric data (WB data, ELISA), and two-way ANOVA
was used to analyse LDH activity. To avoid risk of bias, all
investigators performing the laboratory analyses worked with
coded thus blinded samples. p < 0.05 was considered
significant.
Results
Prolonged Exposure to Helium Plasma Reduces
Hypoxia-Induced Cell Damage in HUVEC
The effect of hypoxia-induced cell damage was evaluated by
LDH activity, and mean LDH activity of the baseline sample
(T0) was used as reference (set as 1.0). We performed exper-
iments using two different plasma concentrations (5% and
10%) with a prehypoxic incubation time of 1 h, but observed
no protection against hypoxia (see supplementary data S1).
After prolongation of the prehypoxic incubation time to 2 h
(using 10% plasma in cell culture medium), we demonstrated
cell protection: plasma obtained 6 h after helium treatment
(T2) mean 95% CI [lower limit, upper limit] 0.86 [0.77;
0.95] reduced hypoxia-induced cell damage compared with
baseline (= reference) plasma, p < 0.05. Plasma obtained at
the other time points, i.e. directly after helium inhalation
(T1) and 24 h after helium inhalation (T3), did not protect
HUVEC cells against hypoxia (see Fig. 2a, b). Plasma obtain-
ed after treatment with normal air inhalation did not affect
hypoxia-induced cell damage in normal and prolonged expo-
sure, for both 5% and 10% concentrations (see online
supplement, S2).
The Role of Caveolin-1 in Remote Helium Protection
Against Hypoxia
In the plasma of the volunteers, the caveolin-1 levels were
low, and no significant differences between time points
were observed (Fig. 3). Cellular levels of caveolin-1 in
HUVECs were measured by western blot analysis and
corrected for loading control GAPDH levels. In compari-
son with baseline, plasma obtained directly after (T1) and
24 h after (T3) helium inhalation caused a significant in-
crease in cellular caveolin levels T0 = 0.95 [0.86, 1.03],
T1 = 1.1 [0.99, 1.16] and T3 = 1.0 [0.98, 1.15] respective-
ly, p < 0.05. This is shown in Fig. 3b. Surprisingly, plasma
obtained 6 h after helium inhalation (T2) did not signifi-
cantly increase caveolin-1.
In conjunction with increased cellular levels of caveo-
lin, we found decreased levels in the supernatant corre-
sponding time points T1 and T3 compared with baseline
T0 = 1.0 [0.74, 1.20], T1 = 0.8 [0.59, 1.02] and T3 = 0.7
[0.50, 0.96], p < 0.05, Fig. 3c. Additionally, a lack of sig-
nificant decrease at T2 matched the results of the cytosol,
also shown in Fig. 3b. Hypoxia itself (24 h) did not affect
caveolin-1 levels in HUVECs (data not shown).
Cav-1 Transfection Abolishes Remote
Helium-Conditioned Plasma Protection in HUVECs
Exposed to Hypoxia
Transfection with Cav-1 siRNA successfully lowers Cav-
1 levels in Huvecs to 16% compared with Huvecs
transfected with negative control siRNA (Fig. 4b). In
Cav-1 siRNA-transfected Huvecs, the protective effect of
T2 plasma was abolished, showing no difference between
LDH in cells treated with baseline (T0) plasma (25.5
[24.7, 25.8] and 24.6 [23.5, 25.7]) respectively (Fig. 4a).
This indicates that Cav-1 possibly plays a role in helium
remote protection against hypoxia.
The Role of Regulation Kinases in Remote Helium
Protection Against Hypoxia
The levels of HIF1α were determined in the cytosolic
fraction. No differences in the HIF1α levels were ob-
served after incubation with plasma from any of the
time points when compared with baseline; see Fig. 4a.
The levels of ERK1/2 were determined in a similar
fashion, and no differences were observed after incuba-
tion with helium plasma; see Fig. 5b. The ratio of acti-
vated (phosphorylated to total (p/t)) STAT3 showed a
significant increase after incubation with plasma obtain-
ed 24 h after helium inhalation compared with baseline
T0 = 0.7 [0.49, 0.89], T3 = 1.1 [0.81, 1.39], p < 0.05.
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None of the other time points showed increased levels
of activated STAT3, Fig. 5c.
The Role of eNOS in Remote Helium Protection
Against Hypoxia
In the plasma of the volunteers, levels of eNOS were below
the detection limit. In the supernatant of the Huvecs exposed
to 24 h of hypoxia, eNOS levels were also undetectable. After
incubation with plasma, but before start of hypoxia, cells and
supernatant were collected and analysed using western blot
(cells) and ELISA (supernatant). No differences were ob-
served in eNOS levels; see Fig. 6a, b.
Discussion
This is the first study showing that helium induces remote
protection by using plasma from healthy helium-breathing
volunteers. The respective plasma decreased hypoxia-
induced cell damage in Huvecs in vitro. Thus, in addition to
in vivo protection in humans [2], we now show that helium
induces remote conditioning by protecting endothelial cells
in vitro against hypoxia.
When compared with RIPC plasma, helium plasma did not
induce protection against hypoxia-induced cell damage in a
concentration of 5% [18]. Increasing the plasma concentration
to 10% did not result in protection either, yet a prolonged
prehypoxic exposure (2 h) of 10% helium plasma protected
Fig. 3 Effect of remote helium conditioning on caveolin-1 levels in
HUVEC and plasma from volunteers. a ELISA results of caveolin-1 in
plasma from volunteers at different time points. b Summarised western
blot results of caveolin-1 in cell lysate of Huvecs following 24 h of
hypoxia. c Summarised western blot results of caveolin-1 in supernatant
of Huvecs subjected to 24 h of hypoxia. Columns represent means (±
95% CI). *p < 0.05 to baseline
Fig. 2 Effect of remote helium-conditioned plasma on hypoxia-induced
damage in Huvecs. Quantification of lactate dehydrogenase (LDH) activ-
ity as marker of hypoxia-induced cell damage in the supernatant of
Huvecs, following 10% plasma incubation for 2 h prior to start of 24-h
hypoxia. aRelative LDH activity after helium inhalation, baseline (T0) =
1. b Relative LDH activity after control gas inhalation, baseline (T0) = 1.
Columns represent means (± 95% confidence interval (CI)). *p < 0.05
compared with baseline
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endothelial cells against hypoxia. This suggests that helium
plasma is less potent to induce protection against hypoxia than
RIPC plasma. A possible explanation could be that helium
was applied as a continuous stimulus, and preconditioning is
generally more pronounced after repetitive stimuli [21].
Further research is needed to elucidate whether the stimulus
by helium inhalation can be optimised and the protective po-
tency of helium plasma can be increased.
Surprisingly, helium plasma obtained 6 h after helium in-
halation did not show increased caveolin-1 levels in the cells
after hypoxia. This in contrast to the fact that helium plasma
from this time point protected the cells against hypoxia-
induced cell damage (as measured by LDH activity levels).
Unfortunately, no other data are available regarding caveolin
levels in endothelium following remote conditioning.
This lack of caveolin-1 increase after helium-containing
plasma obtained after 6 h can be considered in two different
ways: first, one can conclude that helium conditioning is not
mediated by caveolin-1, and consider the increased levels of
caveolin-1 after exposure to plasma obtained after 30 min and
24 h as epiphenomena and unrelated to helium conditioning.
However, considering the fact that caveolin is strictly balanced
and continuously regulated, we hypothesised that increased
caveolin-1 levels have preceded the actual protection we dem-
onstrated in the plasma taken 6 h after helium inhalation. To test
this, we repeated the experiment in caveolin-1 siRNA-
Fig. 5 Effect of remote helium conditioning on signal transduction
kinases in Huvecs. a Western blot results of the ratio of HIF1α
compared with GAPDH loading controls in cell lysate of Huvecs
following 24 h of hypoxia. b Western blot results of the ratio of ERK1/
2 and loading control GAPDH in cell lysate of Huvecs following 24 h of
hypoxia. c Western blot results of activated (phosphorylated to total
STAT3) STAT3 in cell lysate of Huvecs following 24 h of hypoxia.
Columns represent means (± 95% CI). *p < 0.05 to baseline
Fig. 4 Cav-1 transfection
abolishes remote helium-
conditioned plasma protection in
Huvecs exposed to hypoxia. a
Levels of cellular Cav-1 in
Huvecs transfected with Cav-1
siRNA (16%) and negative con-
trol siRNA (100%). Columns
represent means (± 95% CI). b
Absolute LDH activity of Cav-1-
transfected Huvecs incubated
with plasma from baseline and 6 h
after helium treatment. Columns
represent means (± 95% confi-
dence interval (CI)). *p < 0.05
compared with baseline. Huvecs
human umbilical vein endothelial
cells
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transfected Huvecs and showed that the protective effect of T2
plasma was abolished. This could indicate that caveolin-1 plays
a role in helium remote protection against hypoxia.
Caveolins and Remote Preconditioning
Three different caveolin isomeres are present, all with different
origin and functions. Caveolin-3 typically originates from
cardiomyocytes, whereas caveolin-1 is mostly found in endothe-
lial cells. A previous study showed that helium treatment of
endothelial cells lowers levels of caveolin-1 in Huvecs and in-
creases levels of circulating caveolin-1 in the supernatant of
these cells [19]. Additionally, helium postconditioning leads to
increased levels of circulating caveolin-3, as well as increased
levels of caveolin-1 and -3 in the myocardial area at risk [22].
Considering these data, we expected that helium would result in
increased circulating levels of caveolin-1 in blood. However, the
data from the current study do not support this hypothesis. This
could either mean that circulating levels of caveolin-1 are not the
mediating factor in helium remote preconditioning, or the circu-
lating amounts were below the detection limit. Ourmeasurement
could have been influenced by dilution of caveolin-1 in the
systemic circulation.
Furthermore, caveolins are primarily concentrated in the
cholesterol-enriched membranes, with reports indicating that
cell stress can induce the translocation of caveolins from plas-
ma membranes to mitochondrial membranes and other non-
caveolae membranes [23]. Measurements of caveolin in
membrane/particulate fractions could have yielded different
results, but were not measured during the experiments.
Therefore, definitive conclusions should only be drawn very
carefully.
Caveolins are not only involved in conveying a remote
conditioning signal, but also in mediating an effect within
the target organ. Ischemic and anaesthetic preconditioning in
cardiomyocytes involved increased levels of caveolin-3 in the
target organ [16, 24]. Protection of ischemic preconditioning
was abrogated when caveolin-3 was absent in caveolin-3
knockout mice, proving that caveolin in the target organ is
essential [16, 25]. In the present study, we showed increased
levels of caveolin-1 in Huvecs after exposure to helium plas-
ma obtained 30 min and 24 h after helium treatment. Under
normal circumstances, caveolin regulates endocytosis and
exocytosis in cells, is continuously recycled, and total levels
of caveolins are balanced [26, 27]. We found that helium plas-
ma increased the caveolin-1 cellular level and decreased the
buoyant level, possibly indicating that less caveolin-1 is se-
creted to the supernatant by exocytosis. Additional experi-
ments investigating the effect of 2 h of prehypoxic exposure
to 10% helium plasma without hypoxia showed lowered
caveolin-1 levels, but not significantly (supplemental data
S3). This indicates that hypoxia, or the damaging factor, is
needed to reveal upregulation of caveolin-1. Hypoxia itself
does not increase caveolin-1 levels because caveolin-1 levels
after exposure to baseline plasma remained unaffected.
Remote Helium Preconditioning and the RISK
and SAFE Pathway
The role of STAT3 and STAT5 activation in RIPC is not
entirely clear and appears to be dependent of species,
targeted organs and cell types in vitro [28, 29]. In the
present study, we demonstrated that plasma obtained
24 h after helium inhalation activated STAT3 in compar-
ison with baseline. None of the other time points activated
STAT3. These data suggest that helium remote protection
is not mediated by STAT3 activation.
Fig. 6 The role of eNOS in
remote helium conditioning. a
Western blot results of the ratio of
activated (phosphorylated to
total) eNOS in Huvecs after
prehypoxic exposure to plasma. b
Results of ELISA measurements
of eNOS in the supernatant of
Huvecs after prehypoxic
exposure to plasma. Columns
represent means (± 95% CI).
*p < 0.05 to baseline
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Prolonged hypoxia (24 h) previously caused activation of
STAT3 by regulating HIF1α in Huvecs [30]. The difference
between these studies is the presence of human plasma, which
could have influenced STAT3 activation. Our data show that
helium plasma obtained 24 h after inhalation activates STAT3
and could be a possible mediator of the late phase of helium
preconditioning which was demonstrated before [2].
RIPC plasma induces protection against hypoxia, in which
upregulation of HIF1α and activation of ERK1/2 is involved
[18]. In contrast to these findings, the protection against hyp-
oxia from helium plasma does not involve upregulation of
HIF1α and ERK1/2. Yet another example of different mech-
anisms of action is ERK1/2, Akt [31], GSK3B and PKC-ε
[32], all of which are involved in (remote) ischemic precon-
ditioning, but not in helium remote conditioning.
These data indicate that helium remote conditioning in-
volves a different set of mediators that are not linked to the
RISK pathway but rather to caveolin secretion and extracellu-
lar vesicle formation.
Very recent evidence from the literature links extracellular
vesicle release to the protection of the heart [33]. Regarding
helium and organ protection, a recent in vitro study of our
group showed that helium treatment induces the release of
caveolin into the supernatant of endothelial cells [19].
Interestingly, the supernatant of these cells, which contained
increased levels of caveolin, was able to reduce the permeabil-
ity of another set of remote endothelial cells. These findings,
together with another earlier study showing that helium expo-
sure could increase microparticle production in endothelial
cells [34], might support the hypothesis that the production
of microparticles might be linked or even mediated via cave-
olin levels in the supernatant and might be in part responsible
for the observed effects of helium [19].
Nanoparticle tracking analysis of the helium-treated super-
natant indeed showed an increased amount of particles re-
leased after 6 h compared with control gas [19]. This effect
was present after 6 h, was reduced after 12 h and even
abolished after 24 h. Because of the timing and the size of
the particles (caveolin can produce varying vesicles from 50
to 100 nm in size [35]), the data suggest that these particles are
caveolin-1 related, although this cannot be proven with our
current experiments.
Thus even though the timing of the increase matches our
present results, further research is needed to confirm this pos-
sible connection in humans in vivo.
Caveolin-1 and eNOS
Regulation of eNOS is complex and negatively regulated by
caveolin-1 [36]. After 24 h of hypoxia, levels of eNOS in the
supernatant were below detection limit. This concurs with
previous research demonstrating that hypoxia decreases
eNOS activation in HUVECs but not in arterial endothelial
cells [37]. Exposure to helium plasma for 2 h without hypoxia
showed no significant increases in eNOS levels. In this study,
quiescent HUVECs were used in a model without flow, and
we cannot exclude that this influenced our results [38, 39].
Weakness of this study is the fact that we used plasma from
healthy volunteers, and translating preconditioning from
healthy volunteers to a clinical setting has been proven difficult.
Besides this, in vitro protection of endothelial cells does not
mean that in vivo protection of endothelial cells is also possible.
It has to be considered that at the time of the protection
against hypoxia (6 h), no effect in the cells on caveolin levels
is seen, only before and after this time point. Our previous
research showed a matching timeframe for increased caveolin
in the supernatant [19], but did not focus on protection against
hypoxia. These previous findings led to our hypothesis that
increased caveolin-1 levels have preceded the actual protection,
and the additional knockdown experiments confirmed this.
In conclusion, helium has the capacity to induce remote
conditioning in humans and the ability to protect remote or-
gans against ischemia-reperfusion injury. Helium is easy to
administer, readily available and has no side effects. Helium,
alone or in combination with other conditioning strategies,
could be a promising conditioning agent to reduce ischemia-
reperfusion injury in a clinical setting.
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